title: Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, CRB 186-Oncology, Baltimore, MD 21231, USA. sboikos1@jhmi.edu
authors.forename: Sosipatros A
authors.initials: SA
authors.lastname: Boikos
authors.forename: Hans-Joerg
authors.initials: HJ
authors.lastname: Hammers
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D000069448:Denosumab; D004164:Diphosphonates / Q000008:administration & dosage*; D018450:Disease Progression; D004351:Drug Resistance; D017809:Fatal Outcome; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007093:Imidazoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000150:complications / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D018570:Risk Assessment; D000077211:Zoledronic Acid
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D007093:Imidazoles; D010281:Parathyroid Hormone; D000069448:Denosumab; D000077211:Zoledronic Acid